The Efficacy and Safety of Pembrolizumab in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2025-06-15 DOI:10.1111/cen.15291

Langyu Xu, Xingxing Dong, Tong Deng, Fang Lu, Weizhen Chen, Gaosong Wu

{"title":"The Efficacy and Safety of Pembrolizumab in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.","authors":"Langyu Xu, Xingxing Dong, Tong Deng, Fang Lu, Weizhen Chen, Gaosong Wu","doi":"10.1111/cen.15291","DOIUrl":null,"url":null,"abstract":"Background: In most existing clinical studies, Pembrolizumab combined therapy has shown good efficacy for ATC. However, the results of this therapy in some other studies have been controversial, and there is a lack of relevant evidence. In this study, we conducted a meta-analysis of survival data, tumor responses, and adverse events.Methods: The online databases (PubMed, EMBASE, and Cochrane Library) were thoroughly searched to collect eligible studies fully. The data were extracted and combined into the meta-analysis. The main outcomes included objective response rate (ORR), stable disease (SD), disease control rate (DCR), median overall survival (mOS), and adverse events (AEs).Result: Our meta-analysis included 8 studies. The pooled ORR, SD, and DCR were 46.0%, 20%, and 74%. Pooled mOS was 9.62 months. Most patients went through grades 1 or 2 AEs. The incidence of grade ≥ 3 Ads was significantly lower, rarely exceeding 5%.Conclusions: Our meta-analysis showed that Pembrolizumab has potential antitumor implications in ATC and is extremely well tolerated.","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cen.15291","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In most existing clinical studies, Pembrolizumab combined therapy has shown good efficacy for ATC. However, the results of this therapy in some other studies have been controversial, and there is a lack of relevant evidence. In this study, we conducted a meta-analysis of survival data, tumor responses, and adverse events.

Methods: The online databases (PubMed, EMBASE, and Cochrane Library) were thoroughly searched to collect eligible studies fully. The data were extracted and combined into the meta-analysis. The main outcomes included objective response rate (ORR), stable disease (SD), disease control rate (DCR), median overall survival (mOS), and adverse events (AEs).

Result: Our meta-analysis included 8 studies. The pooled ORR, SD, and DCR were 46.0%, 20%, and 74%. Pooled mOS was 9.62 months. Most patients went through grades 1 or 2 AEs. The incidence of grade ≥ 3 Ads was significantly lower, rarely exceeding 5%.

Conclusions: Our meta-analysis showed that Pembrolizumab has potential antitumor implications in ATC and is extremely well tolerated.

查看原文本刊更多论文

派姆单抗治疗间变性甲状腺癌的疗效和安全性：一项系统综述和荟萃分析。

背景：在大多数现有的临床研究中，派姆单抗联合治疗ATC显示出良好的疗效。然而，在其他一些研究中，这种治疗的结果一直存在争议，缺乏相关证据。在这项研究中，我们对生存数据、肿瘤反应和不良事件进行了荟萃分析。方法：全面检索在线数据库（PubMed、EMBASE和Cochrane Library），充分收集符合条件的研究。数据被提取并合并到meta分析中。主要结局包括客观缓解率（ORR）、疾病稳定率（SD）、疾病控制率（DCR）、中位总生存期（mOS）和不良事件（ae）。结果：我们的荟萃分析包括8项研究。总ORR、SD和DCR分别为46.0%、20%和74%。合并最大存活期为9.62个月。大多数患者经历了1级或2级ae。≥3级ad的发生率显著降低，很少超过5%。结论：我们的荟萃分析显示，Pembrolizumab在ATC中具有潜在的抗肿瘤作用，并且耐受性非常好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.